Neurofibromin 1–mutant (
Rebecca Lock, Rachel Ingraham, Ophélia Maertens, Abigail L. Miller, Nelly Weledji, Eric Legius, Bruce M. Konicek, Sau-Chi B. Yan, Jeremy R. Graff, Karen Cichowski
Combined cabozantinib and PD901 treatment induces tumor regression in vivo.